Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline
Open accessThe DOI matches its Crossref record; 262 of the 262 references it cites were found in a registry or an index.
Abstract
The aim of this international guideline on dementia was to present a peer‐reviewed evidence‐based statement for the guidance of practice for clinical neurologists, geriatricians, psychiatrists, and other specialist physicians responsible for the care of patients with dementia. It covers major aspects of diagnostic evaluation and treatment, with particular emphasis on the type of patient often referred to the specialist physician. The main focus is Alzheimer's disease, but many of the recommendations apply to dementia disorders in general. The task force working group considered and classified evidence from original research reports, meta‐analysis, and systematic reviews, published before January 2006. The evidence was classified and consensus recommendations graded according to the EFNS guidance. Where there was a lack of evidence, but clear consensus, good practice points were provided. The recommendations for clinical diagnosis, blood tests, neuroimaging, electroencephalography (EEG), cerebrospinal fluid (CSF) analysis, genetic testing, tissue biopsy, disclosure of diagnosis, treatment of Alzheimer's disease, and counselling and support for caregivers were all revised when compared with the previous EFNS guideline. New recommendations were added for the treatment of vascular dementia, Parkinson's disease dementia, and dementia with Lewy bodies, for monitoring treatment, for treatment of behavioural and psychological symptoms in dementia, and for legal issues. The specialist physician plays an important role together with primary care physicians in the multidisciplinary dementia teams, which have been established throughout Europe. This guideline may contribute to the definition of the role of the specialist physician in providing dementia health care.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Studies of interference in serial verbal reactions
Stroop, J. R. (1935) · Journal of Experimental Psychology · doi:10.1037/h0054651 · Cited by 18,622
Pharmacological interventions for somatoform disorders in adults
Kleinstäuber, M., Witthöft, M., Steffanowski, A., van Marwijk, H., Hiller, W., & Lambert, M. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010628.pub2 · Cited by 11,335
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)
Hu, R. J. (2003) · Encyclopedia of the Neurological Sciences · doi:10.1016/b0-12-226870-9/01070-4 · Cited by 9,117
Validity of the Trail Making Test as an Indicator of Organic Brain Damage
Reitan, R. M. (1958) · Perceptual and Motor Skills · doi:10.2466/pms.1958.8.3.271 · Cited by 7,928
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
Self-citationFrontotemporal lobar degeneration: A consensus on clinical diagnostic criteria
Neary, D., Snowden, J. S., Gustafson, L., Passant, U., Stuss, D., Black, S., Freedman, M., Kertesz, A., Robert, P. H., Albert, M., et al. (1998) · Neurology · doi:10.1212/wnl.51.6.1546 · Cited by 5,047
Román, G. C., Tatemichi, T. K., Erkinjuntti, T., Cummings, J. L., Masdeu, J. C., Garcia, J. H., Amaducci, L., Orgogozo, J.-M., Brun, A., Hofman, A., et al. (1993) · Neurology · doi:10.1212/wnl.43.2.250 · Cited by 4,921
McKeith, I. G., Galasko, D., Kosaka, K., Perry, E. K., Dickson, D. W., Hansen, L. A., Salmon, D. P., Lowe, J., Mirra, S. S., Byrne, E. J., et al. (1996) · Neurology · doi:10.1212/wnl.47.5.1113 · Cited by 3,960 · cited 2×
“inent feature of DLB [12] (II), whereas disinhibition and lack of personal concern are characteristic of FTD [40] (II).”
BackgroundSelf-citationShepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
Measurement of Functional Activities in Older Adults in the Community
Pfeffer, R. I., Kurosaki, T. T., Harrah, C. H., Chance, J. M., & Filos, S. (1982) · Journal of Gerontology · doi:10.1093/geronj/37.3.323 · Cited by 2,972
Meta-Analysis: High-Dosage Vitamin E Supplementation May Increase All-Cause Mortality
Miller, E. R., Pastor-Barriuso, R., Dalal, D., Riemersma, R. A., Appel, L. J., & Guallar, E. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-1-200501040-00110 · Cited by 2,577 · cited 1×
“thermore, a large meta-analysis of studies with vitamin E has shown that high-dosage (£400 IU/day) vitamin E supplements may increase all cause mortality (I) [179].”
BackgroundA Modified Card Sorting Test Sensitive to Frontal Lobe Defects
Nelson, H. E. (1976) · Cortex · doi:10.1016/s0010-9452(76)80035-4 · Cited by 2,454
A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C. W., Pfeiffer, E., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704243361704 · Cited by 2,380
Shumaker, S. A., Legault, C., Rapp, S. R., Thal, L., Wallace, R. B., Ockene, J. K., Hendrix, S. L., Jones III, B. N., Assaf, A. R., Jackson, R. D., et al. (2003) · JAMA · doi:10.1001/jama.289.20.2651 · Cited by 2,178
Petersen, R. C., Stevens, J. C., Ganguli, M., Tangalos, E. G., Cummings, J. L., & DeKosky, S. T. (2001) · Neurology · doi:10.1212/wnl.56.9.1133 · Cited by 2,065
Memantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043
Scheltens, P., Leys, D., Barkhof, F., Huglo, D., Weinstein, H. C., Vermersch, P., Kuiper, M., Steinling, M., Wolters, E. C., & Valk, J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.10.967 · Cited by 1,784
Self-citationStatins and the risk of dementia
Jick, H., Zornberg, G., Jick, S., Seshadri, S., & Drachman, D. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03155-x · Cited by 1,759
Doody, R. S., Stevens, J. C., Beck, C., Dubinsky, R. M., Kaye, J. A., Gwyther, L., Mohs, R. C., Thal, L. J., Whitehouse, P. J., DeKosky, S. T., et al. (2001) · Neurology · doi:10.1212/wnl.56.9.1154 · Cited by 1,720
SEMANTIC DEMENTIA: PROGRESSIVE FLUENT APHASIA WITH TEMPORAL LOBE ATROPHY
HODGES, J. R., PATTERSON, K., OXBURY, S., & FUNNELL, E. (1992) · Brain · doi:10.1093/brain/115.6.1783 · Cited by 1,710
Schneider, L. S., Dagerman, K. S., & Insel, P. (2005) · JAMA · doi:10.1001/jama.294.15.1934 · Cited by 1,671 · cited 1×
“There are recent reports that atypical antipsychotic medication may be associated with an increased risk of cerebrovascular events and mortality in elderly patients with dementia [234–237].”
BackgroundBrain Infarction and the Clinical Expression of Alzheimer Disease<subtitle>The Nun Study</subtitle>
Snowdon, D. A. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03540340047031 · Cited by 1,590
McKhann, G. M. (2001) · Archives of Neurology · doi:10.1001/archneur.58.11.1803 · Cited by 1,472
Differential behavioral effects in frontal lobe disease
Benton, A. L. (1968) · Neuropsychologia · doi:10.1016/0028-3932(68)90038-9 · Cited by 1,431
Knopman, D. S., DeKosky, S. T., Cummings, J. L., Chui, H., Corey–Bloom, J., Relkin, N., Small, G. W., Miller, B., & Stevens, J. C. (2001) · Neurology · doi:10.1212/wnl.56.9.1143 · Cited by 1,410
Tariot, P. N., Farlow, M. R., Grossberg, G. T., Graham, S. M., McDonald, S., Gergel, I., & for the Memantine Study Group (2004) · JAMA · doi:10.1001/jama.291.3.317 · Cited by 1,403
Wolozin, B. (2000) · Archives of Neurology · doi:10.1001/archneur.57.10.1439 · Cited by 1,398
McGeer, P. L., Schulzer, M., & McGeer, E. G. (1996) · Neurology · doi:10.1212/wnl.47.2.425 · Cited by 1,367 · cited 1×
“drugs was suggested to be protective against AD in a retrospective analysis of epidemiological data [180].”
BackgroundCSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291
Rivastigmine for Dementia Associated with Parkinson's Disease
Emre, M., Aarsland, D., Albanese, A., Byrne, E. J., Deuschl, G., De Deyn, P. P., Durif, F., Kulisevsky, J., van Laar, T., Lees, A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041470 · Cited by 1,223
Self-citationDonepezil for dementia due to Alzheimer’s disease.
Birks, J. S., & Harvey, R. J. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001190.pub3 · Cited by 1,200
An Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimerʼs Disease
Galasko, D., Bennett, D., Sano, M., Ernesto, C., Thomas, R., Grundman, M., & Ferris, S. (1997) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199700112-00005 · Cited by 1,194
McShane, R., Areosa Sastre, A., & Minakaran, N. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003154.pub5 · Cited by 1,155
(1987) · PubMed · Cited by 1,147
Cost of disorders of the brain in Europe
Andlin‐Sobocki, P., Jönsson, B., Wittchen, H., & Olesen, J. (2005) · European Journal of Neurology · doi:10.1111/j.1468-1331.2005.01202.x · Cited by 1,139
How Effective Are Interventions With Caregivers? An Updated Meta-Analysis
Sorensen, S., Pinquart, M., & Duberstein, P. (2002) · The Gerontologist · doi:10.1093/geront/42.3.356 · Cited by 1,131
The spectrum of behavioral changes in Alzheimer's disease
Mega, M. S., Cummings, J. L., Fiorello, T., & Gornbein, J. (1996) · Neurology · doi:10.1212/wnl.46.1.130 · Cited by 1,115
Jorm, A. F., & Jacomb, P. A. (1989) · Psychological Medicine · doi:10.1017/s0033291700005742 · Cited by 1,114
Clinical trial of indomethacin in Alzheimer's disease
Rogers, J., Kirby, L. C., Hempelman, S. R., Berry, D. L., McGeer, P. L., Kaszniak, A. W., Zalinski, J., Cofield, M., Mansukhani, L., Willson, P., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1609 · Cited by 999
Mulnard, R. A., Cotman, C. W., Kawas, C., van Dyck, C. H., Sano, M., Doody, R., Koss, E., Pfeiffer, E., Jin, S., Gamst, A., et al. (2000) · JAMA · doi:10.1001/jama.283.8.1007 · Cited by 991
A Placebo-Controlled, Double-blind, Randomized Trial of an Extract of Ginkgo Biloba for Dementia
Le Bars, P. L. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03550160047037 · Cited by 966
Risk of Death in Elderly Users of Conventional vs. Atypical Antipsychotic Medications
Wang, P. S., Schneeweiss, S., Avorn, J., Fischer, M. A., Mogun, H., Solomon, D. H., & Brookhart, M. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052827 · Cited by 959
Meta‐Analysis of Psychosocial Interventions for Caregivers of People with Dementia
Brodaty, H., Green, A., & Koschera, A. (2003) · Journal of the American Geriatrics Society · doi:10.1034/j.1600-0579.2003.00210.x · Cited by 952 · cited 1×
“Two metaanalyses [243,244] and one systematic review [245] on”
BackgroundSilverman, D. H. S., Small, G. W., Chang, C. Y., Lu, C. S., de Aburto, M. A. K., Chen, W., Czernin, J., Rapoport, S. I., Pietrini, P., Alexander, G. E., et al. (2001) · JAMA · doi:10.1001/jama.286.17.2120 · Cited by 951
Rosler, M., Anand, R., Cicin-Sain, A., Gauthier, S., Agid, Y., Dal-Bianco, P., Stahelin, H. B., Hartman, R., Gharabawi, M., & Bayer, T. (1999) · BMJ · doi:10.1136/bmj.318.7184.633 · Cited by 943
A 5-month, randomized, placebo-controlled trial of galantamine in AD
Tariot, P. N., Solomon, P. R., Morris, J. C., Kershaw, P., Lilienfeld, S., Ding, C., & the Galantamine USA- Study Group (2000) · Neurology · doi:10.1212/wnl.54.12.2269 · Cited by 921
The diagnosis of Parkinson’s disease
Tolosa, E., Wenning, G., & Poewe, W. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70285-4 · Cited by 902
Gélinas, I., Gauthier, L., McIntyre, M., & Gauthier, S. (1999) · The American Journal of Occupational Therapy · doi:10.5014/ajot.53.5.471 · Cited by 900
(2004) · The Lancet · doi:10.1016/s0140-6736(04)16499-4 · Cited by 892
MR‐based hippocampal volumetry in the diagnosis of Alzheimer's disease
Jack, C. R., Petersen, R. C., O'Brien, P. C., & Tangalos, E. G. (1992) · Neurology · doi:10.1212/wnl.42.1.183 · Cited by 878
Raskind (2000) · doi:10.1212/wnl.54.12.2261 · Cited by 870
Ott, A., Breteler, M. M. B., van Harskamp, F., Claus, J. J., van der Cammen, T. J. M., Grobbee, D. E., & Hofman, A. (1995) · BMJ · doi:10.1136/bmj.310.6985.970 · Cited by 792
Blennow, K., Wallin, A., Ågren, H., Spenger, C., Siegfried, J., & Vanmechelen, E. (1995) · Molecular and Chemical Neuropathology · doi:10.1007/bf02815140 · Cited by 789
Rogers, S. L. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.9.1021 · Cited by 773
Erkinjuntti, T., Kurz, A., Gauthier, S., Bullock, R., Lilienfeld, S., & Damaraju, C. V. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08267-3 · Cited by 752
Rogers, S. L., & Friedhoff, L. T. (1996) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000106895 · Cited by 742
A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD
Winblad, B., Engedal, K., Soininen, H., Verhey, F., Waldemar, G., Wimo, A., Wetterholm, A.-L., Zhang, R., Haglund, A., Subbiah, P., et al. (2001) · Neurology · doi:10.1212/wnl.57.3.489 · Cited by 727
Self-citationImproved discrimination of AD patients using β-amyloid (1-42) and tau levels in CSF
Hulstaert, F., Blennow, K., Ivanoiu, A., Schoonderwaldt, H. C., Riemenschneider, M., Deyn, P. P. D., Bancher, C., Cras, P., Wiltfang, J., Mehta, P. D., et al. (1999) · Neurology · doi:10.1212/wnl.52.8.1555 · Cited by 724 · cited 1×
“[114,119], DLB [120], VaD [121,122], and CJD [123]”
BackgroundBrain Infarction and the Clinical Expression of Alzheimer Disease-Reply
Snowdon, D. A. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03550020046024 · Cited by 674
Sunderland, T., Linker, G., Mirza, N., Putnam, K. T., Friedman, D. L., Kimmel, L. H., Bergeson, J., Manetti, G. J., Zimmermann, M., Tang, B., et al. (2003) · JAMA · doi:10.1001/jama.289.16.2094 · Cited by 656
Screening for dementia with the Memory Impairment Screen
Buschke, H., Kuslansky, G., Katz, M., Stewart, W. F., Sliwinski, M. J., Eckholdt, H. M., & Lipton, R. B. (1999) · Neurology · doi:10.1212/wnl.52.2.231 · Cited by 653
Neuroleptic sensitivity in patients with senile dementia of Lewy body type.
McKeith, I., Fairbairn, A., Perry, R., Thompson, P., & Perry, E. (1992) · BMJ · doi:10.1136/bmj.305.6855.673 · Cited by 624
Self-citationCSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study
Strozyk, D., Blennow, K., White, L. R., & Launer, L. J. (2003) · Neurology · doi:10.1212/01.wnl.0000046581.81650.d0 · Cited by 612
Bozeat, S. (2000) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.69.2.178 · Cited by 603 · cited 21×
“Their presence may contribute to the process of differential diagnosis, e.g. visual hallucinations are a prominent feature of DLB [12] (II), whereas disinhibition and lack of personal concern are characteristic of FTD [40] (II).”
BackgroundInfluentialA 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease
Feldman, H., Gauthier, S., Hecker, J., Vellas, B., Subbiah, P., Whalen, E., & the Donepezil MSAD Study Investigators Group* (2001) · Neurology · doi:10.1212/wnl.57.4.613 · Cited by 601
Boeve, B. F., Silber, M. H., Ferman, T. J., Lucas, J. A., & Parisi, J. E. (2001) · Movement Disorders · doi:10.1002/mds.1120 · Cited by 599
Ginkgo biloba for cognitive impairment and dementia
Birks, J., & Grimley Evans, J. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003120.pub3 · Cited by 581
Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice
Andreasen, N., Minthon, L., Davidsson, P., Vanmechelen, E., Vanderstichele, H., Winblad, B., & Blennow, K. (2001) · Archives of Neurology · doi:10.1001/archneur.58.3.373 · Cited by 573 · cited 1×
“The combination of Ab42 and total tau increases specificity and the negative predictive value (II): AD versus total group other dementias: 58–85% [113]; AD versus FTD: 85% [119]; AD versus DLB and VaD specificity 67% and 48%, respectively, with a negative predictive value of 95% (I) [130].”
BackgroundSelf-citationEstrogen for Alzheimer’s disease in women: Randomized, double-blind, placebo-controlled trial
Henderson, V. W., Paganini-Hill, A., Miller, B. L., Elble, R. J., Reyes, P. F., Shoupe, D., McCleary, C. A., Klein, R. A., Hake, A. M., & Farlow, M. R. (2000) · Neurology · doi:10.1212/wnl.54.2.295 · Cited by 550
Utility of the Apolipoprotein E Genotype in the Diagnosis of Alzheimer's Disease
Mayeux, R., Saunders, A. M., Shea, S., Mirra, S., Evans, D., Roses, A. D., Hyman, B. T., Crain, B., Tang, M.-X., & Phelps, C. H. (1998) · New England Journal of Medicine · doi:10.1056/nejm199802193380804 · Cited by 547
Orgogozo, J.-M., Rigaud, A.-S., Stöffler, A., Möbius, H.-J., & Forette, F. (2002) · Stroke · doi:10.1161/01.str.0000020094.08790.49 · Cited by 539
Rivastigmine for Alzheimer’s disease.
Birks, J. S., Chong, L.-Y., & Grimley Evans, J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001191.pub4 · Cited by 534
Atypical antipsychotics for aggression and psychosis in Alzheimer's disease
Ballard, C. G., Waite, J., & Birks, J. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003476.pub2 · Cited by 525
Rockwood, K., Kirkland, S., Hogan, D. B., MacKnight, C., Merry, H., Verreault, R., Wolfson, C., & McDowell, I. (2002) · Archives of Neurology · doi:10.1001/archneur.59.2.223 · Cited by 516
A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients
Mohs, R. C., Doody, R. S., Morris, J. C., Ieni, J. R., Rogers, S. L., Perdomo, C. A., Pratt, R. D., & for the “312” Study Group (2001) · Neurology · doi:10.1212/wnl.57.3.481 · Cited by 503
To: A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease
(2001) · Neurology · doi:10.1212/wnl.57.11.2153-a · Cited by 489
Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt–Jakob disease
Zerr, I., Pocchiari, M., Collins, S., Brandel, J. P., de Pedro Cuesta, J., Knight, R. S. G., Bernheimer, H., Cardone, F., Delasnerie-Lauprêtre, N., Cuadrado Corrales, N., et al. (2000) · Neurology · doi:10.1212/wnl.55.6.811 · Cited by 481
Scheltens, P., Launer, L. J., Barkhof, F., Weinstein, H. C., & Gool, W. A. (1995) · Journal of Neurology · doi:10.1007/bf00868807 · Cited by 472
Self-citationJelic, V., Johansson, S.-E., Almkvist, O., Shigeta, M., Julin, P., Nordberg, A., Winblad, B., & Wahlund, L.-O. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00153-6 · Cited by 472
Self-citationA randomized controlled trial of prednisone in Alzheimer’s disease
Aisen, P. S., Davis, K. L., Berg, J. D., Schafer, K., Campbell, K., Thomas, R. G., Weiner, M. F., Farlow, M. R., Sano, M., Grundman, M., et al. (2000) · Neurology · doi:10.1212/wnl.54.3.588 · Cited by 464
Zerr, I., Bodemer, M., Gefeller, O., Otto, M., Poser, S., Wiltfang, J., Windl, O., Kretzschmar, H. A., & Weber, T. (1998) · Annals of Neurology · doi:10.1002/ana.410430109 · Cited by 456
The design of a prospective study of pravastatin in the elderly at risk (PROSPER)
Shepherd, J., Blauw, G. J., Murphy, M. B., Cobbe, S. M., Bollen, E. L. E. M., Buckley, B. M., Ford, I., Jukema, J. W., Hyland, M., Gaw, A., et al. (1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00533-0 · Cited by 449
Early diagnosis of alzheimer’s disease: contribution of structural neuroimaging
Chetelat, G. A., & Baron, J.-C. (2003) · NeuroImage · doi:10.1016/s1053-8119(02)00026-5 · Cited by 444
Sjögren, M., Vanderstichele, H., Ågren, H., Zachrisson, O., Edsbagge, M., Wikkelsø, C., Skoog, I., Wallin, A., Wahlund, L.-O., Marcusson, J., et al. (2001) · Clinical Chemistry · doi:10.1093/clinchem/47.10.1776 · Cited by 436
A 7 Minute Neurocognitive Screening Battery Highly Sensitive to Alzheimer's Disease
Solomon, P. R., Hirschoff, A., Kelly, B., Relin, M., Brush, M., DeVeaux, R. D., & Pendlebury, W. W. (1998) · Archives of Neurology · doi:10.1001/archneur.55.3.349 · Cited by 418
Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion
Scheltens, P., Fox, N., Barkhof, F., & De Carli, C. (2002) · The Lancet Neurology · doi:10.1016/s1474-4422(02)00002-9 · Cited by 410
Self-citationA Comprehensive Support Program: Effect on Depression in Spouse-Caregivers of AD Patients
Mittelman, M. S., Ferris, S. H., Shulman, E., Steinberg, G., Ambinder, A., Mackell, J. A., & Cohen, J. (1995) · The Gerontologist · doi:10.1093/geront/35.6.792 · Cited by 396
Donepezil in vascular dementia: A randomized, placebo-controlled study
Wilkinson, D., Doody, R., Helme, R., Taubman, K., Mintzer, J., Kertesz, A., Pratt, R. D., & the Donepezil 308 Study Group* (2003) · Neurology · doi:10.1212/01.wnl.0000078943.50032.fc · Cited by 392
A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer’s disease
Scharf, S., Mander, A., Ugoni, A., Vajda, F., & Christophidis, N. (1999) · Neurology · doi:10.1212/wnl.53.1.197 · Cited by 390
Black, S., Román, G. C., Geldmacher, D. S., Salloway, S., Hecker, J., Burns, A., Perdomo, C., Kumar, D., & Pratt, R. (2003) · Stroke · doi:10.1161/01.str.0000091396.95360.e1 · Cited by 386 · cited 1×
“In the two donepezil studies, there was a significant improvement in the two main outcome parameters (cognitive functions and overall scales), ADL was significantly improved in one and showed a trend for improvement in the second study at the end of treatment period [204,205] (I).”
BackgroundRofecoxib: No effect on Alzheimer’s disease in a 1-year, randomized, blinded, controlled study
Reines, S. A., Block, G. A., Morris, J. C., Liu, G., Nessly, M. L., Lines, C. R., Norman, B. A., & Baranak, C. C. (2004) · Neurology · doi:10.1212/wnl.62.1.66 · Cited by 385
A randomized controlled trial of prednisone in Alzheimer’s disease
Koch, H. J., & Szecsey, A. (2000) · Neurology · doi:10.1212/wnl.55.7.1067 · Cited by 384
Wilcock, G., M??bius, H. J., & St??ffler, A. (2002) · International Clinical Psychopharmacology · doi:10.1097/00004850-200211000-00005 · Cited by 381 · cited 1×
“Two randomized placebo-controlled 6 month studies are available in patients suffering from mild-tomoderate VaD [211,212], using 20 mg/day memantine.”
MethodBrainin, M., Barnes, M., Baron, J. ‐., Gilhus, N. E., Hughes, R., Selmaj, K., & Waldemar, G. (2004) · European Journal of Neurology · doi:10.1111/j.1468-1331.2004.00867.x · Cited by 375
Self-citationTemporal Lobe Regions on Magnetic Resonance Imaging Identify Patients With Early Alzheimer's Disease
Killiany, R. J., Moss, M. B., Albert, M. S., Sandor, T., Tieman, J., & Jolesz, F. (1993) · Archives of Neurology · doi:10.1001/archneur.1993.00540090052010 · Cited by 373
Kanowski, S., Herrmann, W., Stephan, K., Wierich, W., & Hörr, R. (1996) · Pharmacopsychiatry · doi:10.1055/s-2007-979544 · Cited by 369
Holmes, C., Cairns, N., Lantos, P. L., & Mann, A. (1999) · British Journal of Psychiatry · doi:10.1192/bjp.174.1.45 · Cited by 359
Clark, C. M., Xie, S., Chittams, J., Ewbank, D., Peskind, E., Galasko, D., Morris, J. C., McKeel, D. W., Farlow, M., Weitlauf, S. L., et al. (2003) · Archives of Neurology · doi:10.1001/archneur.60.12.1696 · Cited by 357
Practice parameter: Management of dementia (an evidence-based review)
Oken, B. S. (2001) · Neurology · doi:10.1212/wnl.57.12.2323 · Cited by 351
Myocardial Disorders in the Elderly
(1963) · The Lancet · doi:10.1016/s0140-6736(63)90462-8 · Cited by 348
Diagnostic strategies in CADASIL
Markus, H. S., Martin, R. J., Simpson, M. A., Dong, Y. B., Ali, N., Crosby, A. H., & Powell, J. F. (2002) · Neurology · doi:10.1212/wnl.59.8.1134 · Cited by 335
O'Brien, J. T., Colloby, S., Fenwick, J., Williams, E. D., Firbank, M., Burn, D., Aarsland, D., & McKeith, I. G. (2004) · Archives of Neurology · doi:10.1001/archneur.61.6.919 · Cited by 334
Self-citation["The 5 words": a simple and sensitive test for the diagnosis of Alzheimer's disease].
Dubois, B., Touchon, J., Portet, F., Ousset, P., Vellas, B. J., & Michel, B. F. (2002) · PubMed · Cited by 326
Self-citationGalantamine for Alzheimer's disease and mild cognitive impairment
Loy, C., & Schneider, L. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001747.pub3 · Cited by 322
Mittelman, M. S., Ferris, S. H., Steinberg, G., Shulman, E., Mackell, J. A., Ambinder, A., & Cohen, J. (1993) · The Gerontologist · doi:10.1093/geront/33.6.730 · Cited by 314
Dubinsky, R. M., Stein, A. C., & Lyons, K. (2000) · Neurology · doi:10.1212/wnl.54.12.2205 · Cited by 311
Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt–Jakob disease
Otto, M., Wiltfang, J., Cepek, L., Neumann, M., Mollenhauer, B., Steinacker, P., Ciesielczyk, B., Schulz–Schaeffer, W., Kretzschmar, H. A., & Poser, S. (2002) · Neurology · doi:10.1212/wnl.58.2.192 · Cited by 289
The Decreasing Prevalence of Reversible Dementias: An Updated Meta-analysis
Clarfield, A. M. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.18.2219 · Cited by 285
Donepezil for dementia due to Alzheimer's disease
Birks, J., & Harvey, R. J. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001190.pub2 · Cited by 285
EARLY MARKER FOR ALZHEIMER'S DISEASE: THE ATROPHIC HIPPOCAMPUS
De Leon, M., George, A., Stylopoulos, L., Smith, G., & Miller, D. (1989) · The Lancet · doi:10.1016/s0140-6736(89)90911-2 · Cited by 284 · cited 1×
“Hippocampal atrophy is an early and specific marker of the AD process [61–65] (II–IV).”
BackgroundEffects of estrogen on cognition, mood, and cerebral blood flow in AD: A controlled study
Wang, P. N., Liao, S. Q., Liu, R. S., Liu, C. Y., Chao, H. T., Lu, S. R., Yu, H. Y., Wang, S. J., & Liu, H. C. (2000) · Neurology · doi:10.1212/wnl.54.11.2061 · Cited by 283
Accuracy and Reliability of Periodic Sharp Wave Complexes in Creutzfeldt-Jakob Disease
Steinhoff, B. J., Racker, S., Herrendorf, G., Poser, S., Grosche, S., Zerr, I., Kretzschmar, H., & Weber, T. (1996) · Archives of Neurology · doi:10.1001/archneur.1996.00550020074017 · Cited by 281
Leone, M. A., Brainin, M., Boon, P., Pugliatti, M., Keindl, M., & Bassetti, C. L. (2013) · European Journal of Neurology · doi:10.1111/ene.12043 · Cited by 280
Walker, Z. (2002) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.73.2.134 · Cited by 279
COOPER, J. A., SAGAR, H. J., DOHERTY, S. M., JORDAN, N., TIDSWELL, P., & SULLIVAN, E. V. (1992) · Brain · doi:10.1093/brain/115.6.1701 · Cited by 275
Ravina, B. (2005) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2004.050682 · Cited by 273
Prevalence and Impact of Medical Comorbidity in Alzheimer's Disease
Doraiswamy, P. M., Leon, J., Cummings, J. L., Marin, D., & Neumann, P. J. (2002) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/57.3.m173 · Cited by 269
Diagnosis and management of normal-pressure hydrocephalus
Vanneste, J. A. L. (2000) · Journal of Neurology · doi:10.1007/s004150050003 · Cited by 268
Zeman, A. Z. J., Boniface, S. J., & Hodges, J. R. (1998) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.64.4.435 · Cited by 266
Rogers, S. L., Doody, R. S., Pratt, R. D., & Ieni, J. R. (2000) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(00)00067-5 · Cited by 265
Wahlund, L.-O. (2000) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.69.5.630 · Cited by 259
Efficacy of Donepezil in Early-Stage Alzheimer Disease: A Randomized Placebo-Controlled Trial
Seltzer, B. (2004) · Archives of Neurology · doi:10.1001/archneur.61.12.1852 · Cited by 257
Magnetic Resonance Imaging in the Clinical Diagnosis of Creutzfeldt-Jakob Disease
Schröter, A., Zerr, I., Henkel, K., Tschampa, H. J., Finkenstaedt, M., & Poser, S. (2000) · Archives of Neurology · doi:10.1001/archneur.57.12.1751 · Cited by 255
Frontotemporal Dementia: Treatment Response to Serotonin Selective Reuptake Inhibitors
Swartz, J. R., Miller, B. L., Lesser, I. M., & Darby, A. L. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n0506 · Cited by 250
Bryant, J., Clegg, A., Nicholson, T., McIntyre, L., De Broe, S., Gerard, K., & Waugh, N. (2001) · Health Technology Assessment · doi:10.3310/hta5010 · Cited by 246
The burden of brain diseases in Europe
Olesen, J., & Leonardi, M. (2003) · European Journal of Neurology · doi:10.1046/j.1468-1331.2003.00682.x · Cited by 242
Nimodipine for primary degenerative, mixed and vascular dementia
Birks, J., & López-Arrieta, J. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000147 · Cited by 230
Bullock, R., Touchon, J., Bergman, H., Gambina, G., He, Y., Rapatz, G., Nagel, J., & Lane, R. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x56565 · Cited by 228
Andreasen, N., Vanmechelen, E., Van de Voorde, A., Davidsson, P., Hesse, C., Tarvonen, S., Raiha, I., Sourander, L., Winblad, B., & Blennow, K. (1998) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.64.3.298 · Cited by 227
Self-citationBehavioural changes and psychological symptoms in dementia disorders
McKeith, I., & Cummings, J. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70219-2 · Cited by 221
Self-citationRahman, S., Nestor, P. J., Hodges, J. R., Sahakian, B. J., & Deakin, J. B. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1686-5 · Cited by 221
Rates of global and regional cerebral atrophy in AD and frontotemporal dementia
Chan, D., Fox, N. C., Jenkins, R., Scahill, R. I., Crum, W. R., & Rossor, M. N. (2001) · Neurology · doi:10.1212/wnl.57.10.1756 · Cited by 220
Self-citationAntidepressants for treating depression in dementia
Bains, J., Birks, J., & Dening, T. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003944 · Cited by 214
Haloperidol for agitation in dementia
Lonergan, E., Luxenberg, J., Colford, J. M., & Birks, J. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002852 · Cited by 212
Van Gool, W. A., Weinstein, H. C., Scheltens, P. K., & Walstra, G. J. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05623-9 · Cited by 212
Self-citationMedial temporal lobe atrophy on MRI in dementia with Lewy bodies
Barber, R., Gholkar, A., Scheltens, P., Ballard, C., McKeith, I. G., & O’Brien, J. T. (1999) · Neurology · doi:10.1212/wnl.52.6.1153 · Cited by 210 · cited 1×
“In DLB,MRI has been reported to show medial temporal lobe atrophy in a lower frequency than in AD, and therefore the absence of medial temporal lobe atrophy may be suggestive of a diagnosis of DLB [90] (II).”
BackgroundSelf-citationHunt, L. A. (1997) · Archives of Neurology · doi:10.1001/archneur.1997.00550180029008 · Cited by 210
Combining Cognitive Testing and Informant Report to Increase Accuracy in Screening for Dementia
Mackinnon, A., & Mulligan, R. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.11.1529 · Cited by 203
Association between Statin Use and Alzheimer’s Disease
Zamrini, E., McGwin, G., & Roseman, J. M. (2004) · Neuroepidemiology · doi:10.1159/000073981 · Cited by 202
How to improve the clinical diagnosis of Creutzfeldt–Jakob disease
Poser, S., Mollenhauer, B., Krauβ, A., Zerr, I., Steinhoff, B. J., Schroeter, A., Finkenstaedt, M., Schulz-Schaeffer, W. J., Kretzschmar, H. A., & Felgenhauer, K. (1999) · Brain · doi:10.1093/brain/122.12.2345 · Cited by 199
Temporal lobe rating scale: application to Alzheimer's disease and frontotemporal dementia
Galton, C. J. (2001) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.70.2.165 · Cited by 188
Pusey, H., & Richards, D. (2001) · Aging & Mental Health · doi:10.1080/13607860120038302 · Cited by 186
Measurement of quality-of-life changes in patients with Alzheimer's disease.
Dejong, R. N., Osterlund, O. W., & Roy, G. W. (1989) · PubMed · Cited by 186
Amyloid β(1–42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease
Schoonenboom, N. S. M., Pijnenburg, Y. A. L., Mulder, C., Rosso, S. M., Van Elk, E. J., Van Kamp, G. J., Van Swieten, J. C., & Scheltens, P. (2004) · Neurology · doi:10.1212/01.wnl.0000123249.58898.e0 · Cited by 181
Self-citationMRI of Creutzfeldt–Jakob Disease: Imaging Features and Recommended MRI Protocol
Collie, D. A., Sellar, R. J., Zeidler, M., Colchester, A. C. F., Knight, R., & Will, R. G. (2001) · Clinical Radiology · doi:10.1053/crad.2001.0771 · Cited by 180
Role of Cholinesterase Inhibitors in Parkinson’s Disease and dementia with Lewy Bodies
Aarsland, D., Mosimann, U. P., & McKeith, I. G. (2004) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988704267463 · Cited by 180
Self-citationOperational Definitions for the NINDS-AIREN Criteria for Vascular Dementia: An Interobserver Study
van Straaten, E. C. W., Scheltens, P., Knol, D. L., van Buchem, M. A., van Dijk, E. J., Hofman, P. A. M., Karas, G., Kjartansson, O., de Leeuw, F.-E., Prins, N. D., et al. (2003) · Stroke · doi:10.1161/01.str.0000083050.44441.10 · Cited by 178
Self-citationAccess to diagnostic evaluation and treatment for dementia in Europe
Waldemar, G., Phung, K. T. T., Burns, A., Georges, J., Hansen, F. R., Iliffe, S., Marking, C., Rikkert, M. O., Selmes, J., Stoppe, G., et al. (2007) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1652 · Cited by 177
Self-citation3-Year Study of Donepezil Therapy in Alzheimer’s Disease: Effects of Early and Continuous Therapy
Winblad, B., Wimo, A., Engedal, K., Soininen, H., Verhey, F., Waldemar, G., Wetterholm, A.-L., Haglund, A., Zhang, R., & Schindler, R. (2006) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000091790 · Cited by 175
Self-citationSystematic Review of the Diagnostic Accuracy of 99mTc-HMPAO-SPECT in Dementia
Dougall, N. J. (2004) · American Journal of Geriatric Psychiatry · doi:10.1176/appi.ajgp.12.6.554 · Cited by 173
Frontotemporal Dementia: Paroxetine as a Possible Treatment of Behavior Symptoms
Moretti, R., Torre, P., Antonello, R. M., Cazzato, G., & Bava, A. (2003) · European Neurology · doi:10.1159/000067021 · Cited by 172
Donepezil for vascular cognitive impairment
Malouf, R., & Birks, J. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004395.pub2 · Cited by 170
Tau and Aβ42 protein in CSF of patients with frontotemporal degeneration
Riemenschneider, M., Wagenpfeil, S., Diehl, J., Lautenschlager, N., Theml, T., Heldmann, B., Drzezga, A., Jahn, T., Förstl, H., & Kurz, A. (2002) · Neurology · doi:10.1212/wnl.58.11.1622 · Cited by 168
Green, A. J. E., Harvey, R. J., Thompson, E. J., & Rossor, M. N. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00904-5 · Cited by 166
Self-citationWimo, A., Winblad, B., Stoffler, A., Wirth, Y., & Mobius, H. (2003) · PharmacoEconomics · doi:10.2165/00019053-200321050-00004 · Cited by 165
Self-citationDONGEN, M. C. J. M. V. (2003) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(03)00003-9 · Cited by 164
Olin, J. T., Fox, L. S., Pawluczyk, S., Taggart, N. A., & Schneider, L. S. (2001) · The American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200111000-00008 · Cited by 163 · cited 1×
“Carbamazepine [240] and valproic acid [241] have both been used to treat agitation in dementia, but with inconsistent effects (II).”
BackgroundRandomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy
Litvan, I., Phipps, M., Pharr, V. L., Hallett, M., Grafman, J., & Salazar, A. (2001) · Neurology · doi:10.1212/wnl.57.3.467 · Cited by 163
The MRI pattern of frontal and temporal brain atrophy in fronto-temporal dementia
Boccardi, M. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00045-3 · Cited by 163
Fuh, J. L., Teng, E. L., Lin, K. N., Larson, E. B., Wang, S. J., Liu, C. Y., Chou, P., Kuo, B. I. T., & Liu, H. C. (1995) · Neurology · doi:10.1212/wnl.45.1.92 · Cited by 162
Selegiline for Alzheimer's disease
Birks, J., & Flicker, L. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000442 · Cited by 162
Rivastigmine for Alzheimer's disease
Birks, J., Grimley Evans, J., Iakovidou, V., & Tsolaki, M. (2000) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001191 · Cited by 159
Decreased CSF amyloid β42 and normal tau levels in dementia with Lewy bodies
Kanemaru, K., Kameda, N., & Yamanouchi, H. (2000) · Neurology · doi:10.1212/wnl.54.9.1875 · Cited by 157
Ginkgo Biloba for cognitive impairment and dementia
Birks, J., & Grimley Evans, J. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003120 · Cited by 156
Hormone replacement therapy to maintain cognitive function in women with dementia
Hogervorst, E., Yaffe, K., Richards, M., & Huppert, F. A. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003799.pub2 · Cited by 153
Potentially reversible conditions in 1000 consecutive memory clinic patients
Hejl, A. (2002) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.73.4.390 · Cited by 152
Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial
McKeith, I. G., Grace, J. B., Walker, Z., Byrne, E. J., Wilkinson, D., Stevens, T., & Perry, E. K. (2000) · International Journal of Geriatric Psychiatry · doi:10.1002/(sici)1099-1166(200005)15:5<387::aid-gps131>3.0.co;2-9 · Cited by 150
Self-citationTemporal Lobe Atrophy on Magnetic Resonance Imaging in the Diagnosis of Early Alzheimer's Disease
Erkinjuntti, T., Lee, D. H., Gao, F., Steenhuis, R., Eliasziw, M., Fry, R., Merskey, H., & Hachinski, V. C. (1993) · Archives of Neurology · doi:10.1001/archneur.1993.00540030069017 · Cited by 148
Linear measures of atrophy in mild Alzheimer disease.
Frisoni, G. B., Beltramello, A., Weiss, C., Geroldi, C., Bianchetti, A., & Trabucchi, M. (1996) · PubMed · Cited by 142
Piracetam for dementia or cognitive impairment
Flicker, L. A., & Evans, J. G. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001011 · Cited by 139
14-3-3 testing in diagnosing Creutzfeldt–Jakob disease: A prospective study in 112 patients
Lemstra, A. W., van Meegen, M. T., Vreyling, J. P., Meijerink, P. H. S., Jansen, G. H., Bulk, S., Baas, F., & van Gool, W. A. (2000) · Neurology · doi:10.1212/wnl.55.4.514 · Cited by 138
Alzheimer Disease: Operating Characteristics of PET— A Meta-Analysis
Patwardhan, M. B., McCrory, D. C., Matchar, D. B., Samsa, G. P., & Rutschmann, O. T. (2004) · Radiology · doi:10.1148/radiol.2311021620 · Cited by 137
Galantamine for vascular cognitive impairment
Birks, J., & Craig, D. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004746.pub2 · Cited by 136
Frequency oftau mutations in three series of non-Alzheimer's degenerative dementia
Houlden, H., Baker, M., Adamson, J., Grover, A., Waring, S., Dickson, D., Lynch, T., Boeve, B., Petersen, R. C., Pickering-Brown, S., et al. (1999) · Annals of Neurology · doi:10.1002/1531-8249(199908)46:2<243::aid-ana14>3.0.co;2-l · Cited by 135
Contribution of Structural Neuroimaging to the Early Diagnosis of Alzheimer’s Disease
de Leon, M. J., Convit, A., DeSanti, S., Carroll, R., George, A. E., Rusinek, H., Bobinski, M., Wisniewski, H. M., & Louis, L. A. S. (1997) · International Psychogeriatrics · doi:10.1017/s1041610297004900 · Cited by 135
Valproate preparations for agitation in dementia
Lonergan, E., & Luxenberg, J. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003945.pub3 · Cited by 134
Varma, A. R., Adams, W., Lloyd, J. J., Carson, K. J., Snowden, J. S., Testa, H. J., Jackson, A., & Neary, D. (2002) · Acta Neurologica Scandinavica · doi:10.1034/j.1600-0404.2002.1o148.x · Cited by 134
Kapaki, E. (2001) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.71.3.401 · Cited by 133
Ditzler, K. (1991) · PubMed · Cited by 127
Radial width of the temporal horn: a sensitive measure in Alzheimer disease.
Frisoni, G. B., Geroldi, C., Beltramello, A., Bianchetti, A., Binetti, G. G., Bordiga, G., DeCarli, C. S., Laakso, M. P., Soininen, H. S., Testa, C., et al. (2002) · PubMed Central · Cited by 125
Pantoni, L., del Ser, T., Soglian, A. G., Amigoni, S., Spadari, G., Binelli, D., & Inzitari, D. (2005) · Stroke · doi:10.1161/01.str.0000155686.73908.3e · Cited by 123
Galantamine Prolonged-Release Formulation in the Treatment of Mild to Moderate Alzheimer’s Disease
Brodaty, H., Corey-Bloom, J., Potocnik, F. C. V., Truyen, L., Gold, M., & Damaraju, C. R. V. (2005) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000086613 · Cited by 122
Görtelmeyer, R., & Erbler, H. C. (1992) · PubMed · Cited by 121
Clinical Features of Frontotemporal Dementia
Boxer, A. L., & Miller, B. L. (2005) · Alzheimer Disease & Associated Disorders · doi:10.1097/01.wad.0000183086.99691.91 · Cited by 119
A prospective study of CSF markers in 250 patients with possible Creutzfeldt-Jakob disease
Van Everbroeck, B. (2003) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.74.9.1210 · Cited by 117
Tapiola, T., Pirttilä, T., Mehta, P. D., Alafuzofff, I., Lehtovirta, M., & Soininen, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00164-0 · Cited by 117
Auriacombe, S., Pere, J.-J., Loria-Kanza, Y., & Vellas, B. (2002) · Current Medical Research and Opinion · doi:10.1185/030079902125000471 · Cited by 115
The diagnostic value of electroencephalography in mild senile Alzheimer's disease
Claus, J. J., STRIJERS, R. L. M., Jonkman, E. J., de Visser, B. W. O., Jonker, C., Walstra, G. J. M., Scheltens, P., & van Gool, W. A. (1999) · Clinical Neurophysiology · doi:10.1016/s1388-2457(98)00076-5 · Cited by 110
Self-citationRivastigmine for vascular cognitive impairment
Birks, J., McGuinness, B., & Craig, D. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004744.pub3 · Cited by 108
The Swedish National Road Administration
Lundberg, G. A. (1996) · REVUE GENERALE DES ROUTES ET DES AERODROMES · Cited by 104
Comorbidity in Dementia: An Autopsy Study
Fu, C., Chute, D. J., Farag, E. S., Garakian, J., Cummings, J. L., & Vinters, H. V. (2004) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2004-128-32-cid · Cited by 102
Carson, S., McDonagh, M. S., & Peterson, K. (2006) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2005.00566.x · Cited by 102
Barrios, V., Argente, J., Pozo, J., Hervás, F., Muñoz, M. T., Sánchez, J. I., & Hernández, M. (1996) · Hormone Research · doi:10.1159/000185009 · Cited by 101
Vitamin E for Alzheimer's disease and mild cognitive impairment
Isaac, M., Quinn, R., & Tabet, N. (2000) · The Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002854 · Cited by 96
Delusions and hallucinations in dementia with Lewy bodies: Worsening with memantine
Ridha, B. H., Josephs, K. A., & Rossor, M. N. (2005) · Neurology · doi:10.1212/01.wnl.0000172351.95783.8e · Cited by 93
Self-citation
Cited by
Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., & Jones, E. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61349-9 · Cited by 2,336
Alzheimer's disease: Targeting the Cholinergic System
H. Ferreira-Vieira, T., M. Guimaraes, I., R. Silva, F., & M. Ribeiro, F. (2016) · Current Neuropharmacology · doi:10.2174/1570159x13666150716165726 · Cited by 1,551
McKeith, I., O'Brien, J., Walker, Z., Tatsch, K., Booij, J., Darcourt, J., Padovani, A., Giubbini, R., Bonuccelli, U., Volterrani, D., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70057-1 · Cited by 716
Self-citationHead size, age and gender adjustment in MRI studies: a necessary nuisance?
Barnes, J., Ridgway, G. R., Bartlett, J., Henley, S. M. D., Lehmann, M., Hobbs, N., Clarkson, M. J., MacManus, D. G., Ourselin, S., & Fox, N. C. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2010.06.025 · Cited by 518
EFNS guidelines for the diagnosis and management of Alzheimer's disease
Hort, J., O’Brien, J. T., Gainotti, G., Pirttila, T., Popescu, B. O., Rektorova, I., Sorbi, S., Scheltens, P., & Dementia, O. B. O. T. E. S. P. O. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03040.x · Cited by 490
Self-citation
Metadata
- Authors
- Waldemar, G., Dubois, B., Emre, M., Georges, J., McKeith, I. G., Rossor, M., Scheltens, P., Tariska, P., & Winblad, B.
- Venue
- European Journal of Neurology
- Publisher
- Wiley
- Published
- 2007-01
- Volume
- 14
- Issue
- 1
- Pages
- e1-26
- ISSN
- 1351-5101 (ISSN-L)
- 1468-1331
- OpenAlex
- W2091524551
- Cited by
- 617
- References
- 262
- FWCI
- 26.21
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.